SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- and long-acting insulins.

California is the first state in the country to partner with a nonprofit to develop, produce and sell its own insulin.

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines and biosimilars to U.S. patients, today announced the availability of two new products: insulin glargine-yfgn ...

CivicaScript, a nonprofit generic drug company, has launched insulin glargine-yfgn and ustekinumab-aauz, expanding its national portfolio of low-cost treatments. The insulin product, which is ...

Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...

Among 475 patients randomized in a 1:1:1:1 fashion, those on one of three doses of injectable tirzepatide -- 5 mg, 10 mg, or 15 mg -- in addition to insulin glargine saw a significantly greater mean ...

Discover comprehensive details about Insulin glargine, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

The authors say there has been a recent uptick in hosptial admissions from hypoglycemic events, and that a therapy to address this is needed. A review of 15 studies has found that insulin degludec, ...

SAN DIEGO — For the treatment of type 2 diabetes, the ultra-long–acting, once-daily basal insulin degludec (Tresiba, Novo Nordisk) is as safe in cardiovascular terms as insulin glargine and is ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and methods ...

Please provide your email address to receive an email when new articles are posted on . Insulin glargine and the GLP-1 receptor agonist liraglutide are more effective at achieving an HbA1c of less ...